The Role of Cost-Effectiveness Analysis in the Era of Pharmacogenomics

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.22, Iss.8, 2004-01, pp. : 481-493

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost–effectiveness analysis in pharmacogenomics

By Payne Katherine Shabaruddin Fatiha H

Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. : 643-646

Future Medicine

Access to resources Recommend Favorite

An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

By Phillips Kathryn A Veenstra David Bebber Stephanie Van Sakowski Julie

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 231-239

Future Medicine

Access to resources Recommend Favorite

On Pharmacogenomics and Cost-Effectiveness Analysis at the Individual Level

By Adis International Limited

PharmacoEconomics, Vol. 23, Iss. 5, 2005-01 ,pp. : 527-527

Adis International

Access to resources Recommend Favorite

Pharmacogenomics and the Evolution of Healthcare: Is it Time for Cost-Effectiveness Analysis at the Individual Level?

By Bala M.V.

PharmacoEconomics, Vol. 22, Iss. 8, 2004-01 ,pp. : 495-498

Adis International

Access to resources Recommend Favorite

Does Pharmacogenomics Provide an Ethical Challenge to the Utilisation of Cost-Effectiveness Analysis by Public Health Systems?

By Adam La Caze

PharmacoEconomics, Vol. 23, Iss. 5, 2005-01 ,pp. : 445-447

Adis International

Access to resources Recommend Favorite